Associated Papers
Therapeutic advances and application of PARP inhibitors in breast cancer.
Zhou T et al.
Translational Oncology, 2025
Exploration of poly (ADP-ribose) polymerase inhibitor resistance in the treatment of BRCA1/2-mutated cancer.
Wu S et al.
Genes, Chromosomes & Cancer, 2024
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
Li S et al.
Journal of Hematology & Oncology, 2022
The expanding universe of PARP1-mediated molecular and therapeutic mechanisms.
Huang D et al.
Molecular Cell, 2022
Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.
Mekonnen N et al.
Frontiers in Oncology, 2022
PARP1: Structural insights and pharmacological targets for inhibition.
Spiegel JO et al.
Dna Repair, 2021
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Kim DS et al.
Experimental & Molecular Medicine, 2021
PARP inhibition in treatment of pancreatic cancer.
Hammel P et al.
Expert Review of Anticancer Therapy, 2020
Bridging of DNA breaks activates PARP2-HPF1 to modify chromatin.
Bilokapic S et al.
Nature, 2020
Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases.
Sun J et al.
Nature Communications, 2019
31320627 (PubMed )
Supplement: 41467_2019_10987_MOESM6_ESM.xlsx › Sheet1
Defective homologous recombination DNA repair as therapeutic target in advanced chordoma.
Gröschel S et al.
Nature Communications, 2019
Dissecting PARP inhibitor resistance with functional genomics.
Pettitt SJ et al.
Current Opinion in Genetics & Development, 2019
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.
Pettitt SJ et al.
Nature Communications, 2018
Select a paper to view details